FI885559A0 - Anvaendning av d-cykloserin och dess prodrug som cognition oekande medel. - Google Patents

Anvaendning av d-cykloserin och dess prodrug som cognition oekande medel.

Info

Publication number
FI885559A0
FI885559A0 FI885559A FI885559A FI885559A0 FI 885559 A0 FI885559 A0 FI 885559A0 FI 885559 A FI885559 A FI 885559A FI 885559 A FI885559 A FI 885559A FI 885559 A0 FI885559 A0 FI 885559A0
Authority
FI
Finland
Prior art keywords
prodrug
oekande
cycloserin
medel
anvaendning
Prior art date
Application number
FI885559A
Other languages
English (en)
Inventor
Alex A Cordi
Gail E Handelmann
Joseph B Monahan
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of FI885559A0 publication Critical patent/FI885559A0/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FI885559A 1987-12-01 1988-11-30 Anvaendning av d-cykloserin och dess prodrug som cognition oekande medel. FI885559A0 (fi)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/127,121 US4904681A (en) 1987-12-01 1987-12-01 D-cycloserine and its prodrugs as cognitive enhancers

Publications (1)

Publication Number Publication Date
FI885559A0 true FI885559A0 (fi) 1988-11-30

Family

ID=22428413

Family Applications (1)

Application Number Title Priority Date Filing Date
FI885559A FI885559A0 (fi) 1987-12-01 1988-11-30 Anvaendning av d-cykloserin och dess prodrug som cognition oekande medel.

Country Status (20)

Country Link
US (1) US4904681A (fi)
EP (2) EP0319824B1 (fi)
JP (2) JPH0621065B2 (fi)
KR (1) KR0134198B1 (fi)
AT (1) ATE68698T1 (fi)
AU (4) AU622630B2 (fi)
CA (1) CA1328617C (fi)
DE (1) DE3865817D1 (fi)
DK (1) DK173589B1 (fi)
ES (1) ES2040314T3 (fi)
FI (1) FI885559A0 (fi)
GR (1) GR3003571T3 (fi)
IE (1) IE61825B1 (fi)
IL (1) IL88531A (fi)
NO (1) NO885337D0 (fi)
NZ (1) NZ227131A (fi)
PH (1) PH26467A (fi)
PT (1) PT89109B (fi)
WO (1) WO1989005144A1 (fi)
ZA (1) ZA888981B (fi)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5187171A (en) * 1989-01-09 1993-02-16 G. D. Searle & Co. Use of a glycine b partial agonist as an antipsychotic
US5061721A (en) * 1989-03-15 1991-10-29 G. D. Searle & Co. Composition containing d-cycloserine and d-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5260324A (en) * 1990-02-06 1993-11-09 G. D. Searle & Company Composition containing D-cycloserine and D-alanine for memory and learning enhancement or treatment of a cognitive or psychotic disorder
US5066665A (en) * 1990-05-21 1991-11-19 Warner-Lambert Co. Substituted isoxazolidin-3-ones and derivatives thereof acting at muscarinic receptors
JPH07505908A (ja) * 1992-09-28 1995-06-29 マックセチーニ、マリア　ルイザ Ｎｍｄａ受容体のアロステリックモジュレーター
US5428069A (en) * 1993-01-11 1995-06-27 The United States Of America As Represented By The Department Of Health & Human Services Treating cognition with, aminocyclopropanecarboxylic derivatives
US5523323A (en) * 1993-09-14 1996-06-04 Maccecchini; Maria-Luisa Use of partial agonists of the NMDA receptor to reduce opiate induced tolerance and dependence
NZ260302A (en) * 1994-04-13 1996-05-28 New Zealand Meat Ind Res Inst Treating bait aversion by including substances which disrupt the associative learning process into bait compositions
WO1996015787A1 (en) * 1994-11-23 1996-05-30 G.D. Searle & Co. Use of amino-isoxazolidone compounds for treatment of memory impairment following traumatic brain injury
AU4019395A (en) 1994-11-23 1996-06-17 G.D. Searle & Co. Use of amino-isoxazolidone compounds for improvement of implicit memory
ATE204852T1 (de) * 1995-02-15 2001-09-15 Bearsden Bio Inc Alkylcarboxy-aminosäure modulatoren für den kainat-rezeptor
US6355681B2 (en) * 1995-12-07 2002-03-12 Glytech, Inc. Glycine substitutes and precursors for treating a psychosis
PT871440E (pt) * 1995-12-07 2006-07-31 Daniel C Javitt Tratamento de sintomas negativos e cognitivos de esquizofrenia com antagonistas da captacao de glicina
US6361957B1 (en) * 1999-08-03 2002-03-26 Glytech, Inc. Assay for D-serine transport antagonist and use for treating psychosis
FR2742748B1 (fr) * 1995-12-21 1998-01-30 Adir Nouveau derive de 4-imidazolidinone, son procede de preparation et les compositions pharmaceutiques qui le contiennent
KR100396114B1 (ko) * 1996-10-31 2003-11-20 동아제약 주식회사 D-시클로세린의 제조방법
AU765603C (en) * 1998-04-14 2004-08-05 General Hospital Corporation, The Methods for treating neuropsychiatric disorders
DE69930624T2 (de) * 1998-06-10 2006-09-14 Meiji Seika Kaisha Ltd. Arzneimittel für hinterstrangataxie und zusammensetzung zur behandlung von hinterstrangataxie
US20040122090A1 (en) * 2001-12-07 2004-06-24 Lipton Stuart A. Methods for treating neuropsychiatric disorders with nmda receptor antagonists
US20060252761A1 (en) * 2001-03-29 2006-11-09 Michael Davis Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine
AU2002311784B2 (en) * 2001-03-29 2007-11-22 Michael Davis Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
EP1389181A4 (en) 2001-04-02 2005-10-19 Panorama Res Inc ANTIOXIDANT NITROXIDES AND NITRONES AS THERAPEUTIC AGENTS
US7160913B2 (en) * 2002-09-13 2007-01-09 Thomas Jefferson University Methods and kit for treating Parkinson's disease
KR20060030469A (ko) 2003-05-27 2006-04-10 포레스트 래보러토리즈, 인코포레이티드 우울증 및 그 밖의 기분장애의 치료를 위한 ｎｍｄａ수용체 길항제 및 선택적 세로토닌 재흡수 억제제의 배합물
EP1660634A4 (en) * 2003-08-08 2009-02-18 Burnham Inst P16-mediated regulation of NMDA receptors
US7619007B2 (en) * 2004-11-23 2009-11-17 Adamas Pharmaceuticals, Inc. Method and composition for administering an NMDA receptor antagonist to a subject
KR101406456B1 (ko) * 2005-04-06 2014-06-20 아다마스 파마슈티칼스, 인코포레이티드 Ｃｎｓ 장애의 치료를 위한 방법 및 조성물
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
US9101612B2 (en) 2010-02-11 2015-08-11 Northwestern University Secondary structure stabilized NMDA receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
MX2019001322A (es) 2016-08-01 2019-09-11 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
BR112019001923A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores de nmda de espiro-lactama e métodos de sua utilização
EP3427729A1 (en) 2017-07-13 2019-01-16 Paris Sciences et Lettres - Quartier Latin Probenecid for use in treating epileptic diseases, disorders or conditions
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3050800C2 (fi) * 1979-03-22 1989-06-22 Continental Pharma Inc., Bruessel/Bruxelles, Be

Also Published As

Publication number Publication date
GR3003571T3 (fi) 1993-03-16
JPH05201859A (ja) 1993-08-10
IL88531A0 (en) 1989-06-30
KR0134198B1 (ko) 1998-04-21
US4904681A (en) 1990-02-27
DK173589B1 (da) 2001-04-02
ZA888981B (en) 1990-01-31
PH26467A (en) 1992-07-27
AU2813089A (en) 1989-07-05
JPH01193220A (ja) 1989-08-03
DK669088A (da) 1989-06-02
IL88531A (en) 1993-02-21
EP0421997A1 (en) 1991-04-17
EP0319824B1 (en) 1991-10-23
ES2040314T3 (es) 1995-04-01
IE61825B1 (en) 1994-11-30
CA1328617C (en) 1994-04-19
NZ227131A (en) 1991-09-25
AU1083992A (en) 1992-05-07
JPH0621065B2 (ja) 1994-03-23
WO1989005144A1 (en) 1989-06-15
DE3865817D1 (fi) 1991-11-28
ATE68698T1 (de) 1991-11-15
KR890009392A (ko) 1989-08-01
EP0319824A1 (en) 1989-06-14
DK669088D0 (da) 1988-11-30
NO885337D0 (no) 1988-11-30
IE883567L (en) 1989-06-01
PT89109B (pt) 1993-07-30
AU2631988A (en) 1989-06-01
AU622630B2 (en) 1992-04-16
AU7746794A (en) 1995-01-05
PT89109A (pt) 1989-12-29

Similar Documents

Publication Publication Date Title
FI885559A0 (fi) Anvaendning av d-cykloserin och dess prodrug som cognition oekande medel.
FI881773A0 (fi) Medel foer prevention och behandling av retrovirusinfektioner.
FI882742A (fi) Vaordande medel och dessa innehaollande kompositioner.
DE3779053D1 (fi)
FI884944A0 (fi) Foerfarande och anordning foer selektiv bestaemning av halten av ett medel loesligt i loesningsmedel.
FI885877A0 (fi) Fotopolymeriserbar blandning och uppteckningsmaterial som framstaellts av densamma.
FI892960A (fi) Foerfarande och anordning foer definiering av kanternas laege i roerliga band.
FI885152A0 (fi) Foerfarande foer framstaellning av biologiskt foerstoerbara mikrokapslar som innehaoller vattenloesliga peptider och proteiner och medelst detta foerfarande framstaellda mikrokapslar.
FI874966A (fi) Saett och anlaeggning foer uppfyllning av borrhaol.
FI945626A (fi) Menetelmä 2,2-difluoriketeenisilyyliasetaalien ja alfa, alfa-difluori-beta-silyylioksi-1,3-dioksolaani-4-propaanihappoestereiden valmistamiseksi
FI881126A (fi) Medel foer bekaempning av insekter och kvalster.
ES2085898T3 (es) Tratamiento de la enfermedad hepatobiliar con compuestos 15-cetoprostaglandina.
DE3870954D1 (de) Zahnaerztliche haftmittelzusammensetzung.
FI883315A0 (fi) 1h-pyrazol-1-alkanamider anvaendbara som antiarrytmiska medel och deras framstaellning.
FI881267A0 (fi) Filmer och band.
FI884618A0 (fi) Anordning foer taendning och stabilisering av en svetsbaoge.
FI893707A0 (fi) Foerfarande foer framstaellning av polymerer och deras anvaendning som stabiliseringsaemne foer formaldehyds vattenloesningar.
FI883135A (fi) Homocyklostatin och cyklostatin innehaollande polypeptider som antihypertensiva medel.
FI881154A (fi) Foerfarande foer framstaellning av 5-hydroxidprafenon och dess syraadditionssalter.
FI853883L (fi) Foerfarande foer regenerering av asfaltbetongbelaeggningar och en foer genomfoerande av foerfarandet avsedd mataranordning foer ett medel som aoterstaeller asfaltbetongens egenskaper.
FI874575A0 (fi) Foerfarande och anordning foer att vaelja ett telefonnummer som mottagits av personsoekaren.
DK1260222T3 (da) Farmaceutiske præparater indeholdende hidtil ukendte iso-butenyl-substituerede taxaner
FI874987A0 (fi) Regleranordning och foerfarande foer periodisk uppvaermning.

Legal Events

Date Code Title Description
FA Application withdrawn

Owner name: G D SEARLE & CO.